GALANTAMINE Gazylan XL ®

Clinical Indication

Alzheimer's disease

Date of classification

November 2021

Review date

November 2021

Yellow

Medicines initiated or recommended by a specialist service for prescribing in primary care which do not require initiation or ongoing oversight by the specialist. There are no specific paperwork requirements between provider organisations and a verbal request may be acceptable through advice and guidance as long enough information is provided so that the transfer of care is safe.